Synopsis
Join visionary bioengineer Don Ingber, MD, PhD at Emulate’s headquarters for an exclusive, in‑person fireside chat on the FDA’s bold plan to phase out animal testing—and discover the breakthrough Organ‑Chip technology poised to lead that revolution. Sip craft cocktails, sample gourmet bites, and witness a demo of a brand‑new product that will redefine New Approach Methodologies (NAMs) in drug development. Less than a mile from the Boston convention center, it’s the must‑attend BIO 2025 after‑hours event. RSVP now—space is limited!
What to Expect
Welcome Reception & Networking (5:00 PM)
Ease into the evening with craft cocktails, local brews, and chef-curated appetizers—perfect fuel before your dinner plans.
Live Product Reveal (5:30 PM)
Be among the first to witness a game-changing Organ-Chip solution that will fundamentally transform how NAMs are deployed in preclinical drug development. Demo seats are limited—arrive early!
Fireside Chat (6:00 PM)
Don Ingber, MD, PhD (Wyss Institute & Emulate Scientific Founder) and Lorna Ewart, PhD (Emulate CSO) sit down with leading industry and regulatory voices to unpack the FDA’s groundbreaking roadmap to phase out animal testing and what it means for IND strategy, ISTAND qualification, and expedited reviews. Bring your questions—this is a rare chance to talk policy, science, and implementation with the visionaries driving the change.
Why Attend?
Timely. The FDA has signaled that by 2030 animal studies will be the exception, not the rule. Discover how to stay ahead.
Convenient. We’re just around the corner from the Boston Convention & Exhibition Center—easy to fit between BIO sessions and dinner reservations.
Exclusive. See technology and data that won’t be revealed anywhere else at BIO.
RSVP Required—space is limited.
We look forward to raising a glass with you and charting the next chapter of human‑centric drug development.
